Aevi Genomic Medicine Company
Aevi Genomic Medicine was founded as Medgenics in 2000 in Israel. Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. The company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia. The company tests non-stimulant glutamatergic neuromodulator in subjects with ADHD, as a potential treatment for a sub-population of ADHD patients with genetic mutations that disrupt the mGluR network.
Investment Stage:
N/A
Funding Status:
IPO
Headquarters:
Wayne, Pennsylvania, United States
Industry:
Personalized Medicine
Number Of Exists:
N/A
Investor Type:
N/A
Technology:
Biopharma, Biotechnology, Health Care, Life Science
Employee Number:
11-50
Founded Date:
2000